Professional Documents
Culture Documents
Introduction
Overdose death rates in the U.S. have more than
doubled over the past decade, surpassing motor
vehicle accidents as the leading cause of injury-related
death in the country.1
According to the Centers for Disease Control and
Prevention (CDC), more than 41,500 people died from
an accidental or intentional drug overdose in the U.S.
in 2012 an average of 114 deaths every day.2
Roughly eighty percent of these deaths (over 33,000)
were accidental, and more than 16,000 involved
prescription opioids compared to about 5,900
attributed to heroin.3
Many of these deaths could have been prevented.
Proven strategies are available to reduce the harms
associated with drug misuse, treat dependence and
addiction, improve immediate overdose responses,
enhance public safety and prevent fatalities. These
strategies include expanding access to the life-saving
medicine naloxone and its associated training;
improving fact-based drug education for young people
that includes an overdose prevention and response
component; enacting legal protections that encourage
people to call for help for overdose victims; and
training people how to prevent, recognize and respond
to an overdose.
911 Good Samaritan Limited Immunity Laws
911 Good Samaritan immunity laws provide protection
from arrest and prosecution for witnesses who call 911
or seek emergency medical assistance.
The chance of surviving an overdose, like that of
surviving a heart attack, depends greatly on how fast
one receives medical assistance. Multiple studies
show that most deaths actually occur one to three
hours after the victim has initially ingested or injected
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 2
Similar successes have been reported at communitybased naloxone programs across the country:
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 3
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 4
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 5
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 6
Center for Disease Control and Prevention (CDC), "Prescription Drug Overdose
in the United States: Fact Sheet,"
http://www.cdc.gov/homeandrecreationalsafety/overdose/facts.html; C. M. Jones,
K. A. Mack, and L. J. Paulozzi, "Pharmaceutical Overdose Deaths, United States,
2010," JAMA 309, no. 7 (2013).
2
Margaret Warner, Holly Hedegaard, and Chen Li Hui, "Trends in Drug-Poisoning
Deaths Involving Opioid Analgesics and Heroin: United States, 19992012,"
(National Center for Health Statistics, Centers for Disease Control and Prevention,
2014).
3
Ibid; N. Dasgupta et al., "Observed Transition from Opioid Analgesic Deaths
toward Heroin," Drug Alcohol Depend 145C(2014). Evidence indicates that some
prescription opioid consumers have switched to heroin in recent years. Their
initiation to heroin use seems to have been precipitated by the relatively cheap
price of street heroin compared to prescription opioids,3 lack of access to
prescription opioids perhaps as a result of states efforts to restrict access to
such medications or the difficulties of snorting or injecting new deterrentresistant formulations of prescription drugs. See, e.g., Theodore J. Cicero et al.,
"The Changing Face of Heroin Use in the United States," JAMA Psychiatry (2014);
S. G. Mars et al., ""Every 'Never' I Ever Said Came True": Transitions from Opioid
Pills to Heroin Injecting," Int J Drug Policy 25, no. 2 (2014); C. M. Jones, "Heroin
Use and Heroin Use Risk Behaviors among Nonmedical Users of Prescription
Opioid Pain Relievers - United States, 2002-2004 and 2008-2010," Drug Alcohol
Depend 132, no. 1-2 (2013); S. E. Lankenau et al., "Initiation into Prescription
Opioid Misuse Amongst Young Injection Drug Users," Int J Drug Policy 23, no. 1
(2012); K. M. Peavy et al., ""Hooked on" Prescription-Type Opiates Prior to Using
Heroin: Results from a Survey of Syringe Exchange Clients," J Psychoactive
Drugs 44, no. 3 (2012); R. A. Pollini et al., "Problematic Use of Prescription-Type
Opioids Prior to Heroin Use among Young Heroin Injectors," Subst Abuse Rehabil
2, no. 1 (2011); Theodore J. Cicero, Matthew S. Ellis, and Hilary L. Surratt, "Effect
of Abuse-Deterrent Formulation of Oxycontin," New England Journal of Medicine
367, no. 2 (2012).
4
Peter J. Davidson et al., "Witnessing Heroin-Related Overdoses: The
Experiences of Young Injectors in San Francisco," Addiction 97, no. 12 (2002).
5
M. Tracy et al., "Circumstances of Witnessed Drug Overdose in New York City:
Implications for Intervention," Drug Alcohol Depend 79, no. 2 (2005).
6
Davidson et al., "Witnessing Heroin-Related Overdoses: The Experiences of
Young Injectors in San Francisco; K. C. Ochoa et al., "Overdosing among Young
Injection Drug Users in San Francisco," Addict Behav 26, no. 3 (2001); Robin A.
Pollini et al., "Response to Overdose among Injection Drug Users," American
journal of preventive medicine 31, no. 3 (2006); Tracy et al., "Circumstances of
Witnessed Drug Overdose in New York City: Implications for Intervention."
7
C. J. Banta-Green et al., "Police Officers' and Paramedics' Experiences with
Overdose and Their Knowledge and Opinions of Washington State's Drug
Overdose-Naloxone-Good Samaritan Law," J Urban Health 90, no. 6 (2013).
8
Traci C. Green et al., "Law Enforcement Attitudes toward Overdose Prevention
and Response," Drug and Alcohol Dependence 133, no. 2 (2013); Banta-Green et
al., "Police Officers' and Paramedics' Experiences with Overdose and Their
Knowledge and Opinions of Washington State's Drug Overdose-Naloxone-Good
Samaritan Law."
9
Utah and Indiana adopted laws providing for mitigation in cases of good-faith
reporting of an overdose, but these states do not provide immunity.
10
Banta-Green CJ et al., "Washingtons 911 Good Samaritan Drug Overdose Law
- Initial Evaluation Results," (Alcohol & Drug Abuse Institute, University of
Washington,, 2011); Banta-Green et al., "Police Officers' and Paramedics'
Experiences with Overdose and Their Knowledge and Opinions of Washington
State's Drug Overdose-Naloxone-Good Samaritan Law."
11
Substance Abuse and Mental Health Services Administration, "Opioid Overdose
Prevention Toolkit," (Rockville, Maryland: SAMHSA, 2013); M. M. Straus, U. E.
Ghitza, and B. Tai, "Preventing Deaths from Rising Opioid Overdose in the Us the Promise of Naloxone Antidote in Community-Based Naloxone Take-Home
Programs," Subst Abuse Rehabil 2013, no. 4 (2013).
12
S. Maxwell et al., "Prescribing Naloxone to Actively Injecting Heroin Users: A
Program to Reduce Heroin Overdose Deaths," J Addict Dis 25, no. 3 (2006);
Substance Abuse and Mental Health Services Administration, "Opioid Overdose
Prevention Toolkit."
13
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 7
Release," J Addict Dis 28, no. 2 (2009). See also, Sporer, K.A. Strategies for
preventing heroin overdose. British Medical Journal 326 (22 February 2003): 442444; Galea S., J. Ahern, D. Vlahov, C. Fuller, A.C. Leon, and K. Tardiff. Income
Distribution and Risk of Fatal Drug Overdose in New York City Neighborhoods.
Drug and Alcohol Dependence 70 (2003): 139- 148; Coffin, P.O., M. Tracy, A.
Bucciarelli, D. Ompad, D. Vlahov, S. Galea. Identifying injection drug users at risk
of nonfatal overdose. Academic Emergency Medicine 14 (2007): 616-623; Seal,
K.H. Predictors and Prevention of Non-Fatal Overdose Among Street-Recruited
Heroin Users in the San Francisco Bay Area, 1998-1999. American Journal of
Public Health 1842 (2001): 91; Binswanger et al., "Risk Factors for All-Cause,
Overdose and Early Deaths after Release from Prison in Washington State; I. A.
Binswanger et al., "Return to Drug Use and Overdose after Release from Prison: A
Qualitative Study of Risk and Protective Factors," Addict Sci Clin Pract 7, no. 1
(2012); E. L. Merrall et al., "Meta-Analysis of Drug-Related Deaths Soon after
Release from Prison," Addiction 105, no. 9 (2010).
40
KA Sporer and AH Kral, "Prescription Naloxone: A Novel Approach to Heroin
Overdose Prevention," Ann Emerg Med 49, no. 2 (2007).
41
Binswanger et al., "Mortality after Prison Release: Opioid Overdose and Other
Causes of Death, Risk Factors, and Time Trends from 1999 to 2009."
42
J. Strang, S. M. Bird, and M. K. Parmar, "Take-Home Emergency Naloxone to
Prevent Heroin Overdose Deaths after Prison Release: Rationale and
Practicalities for the N-Alive Randomized Trial," J Urban Health 90, no. 5 (2013);
Wakeman et al., "Preventing Death among the Recently Incarcerated: An
Argument for Naloxone Prescription before Release; Substance Abuse and Mental
Health Services Administration, "Opioid Overdose Prevention Toolkit."
43
Department of Justice, "Attorney General Holder Announces Plans for Federal
Law Enforcement Personnel to Begin Carrying Naloxone," (2014),
http://www.justice.gov/opa/pr/2014/July/14-ag-805.html.
44
Corey S. Davis et al., "Expanded Access to Naloxone among Firefighters, Police
Officers, and Emergency Medical Technicians in Massachusetts," American
Journal of Public Health (2014); Davis et al., "Emergency Medical Services
Naloxone Access: A National Systematic Legal Review."
45
Green et al., "Law Enforcement Attitudes toward Overdose Prevention and
Response."
46
Office of National Drug Control Policy to ONDCP Blog, 2014,
http://www.whitehouse.gov/blog/2014/02/11/5-things-know-about-opioidoverdoses.
47
Ibid.
48
Attorney General Eric Holder, "Remarks at the 2014 Police Executive Research
Forum," (2014).
49
Department of Justice, "Attorney General Holder Announces Plans for Federal
Law Enforcement Personnel to Begin Carrying Naloxone".
50
Beletsky, Rich, and Walley, "Prevention of Fatal Opioid Overdose."
51
T. C. Green et al., "Barriers to Medical Provider Support for Prescription
Naloxone as Overdose Antidote for Lay Responders," Substance use & misuse
48, no. 7 (2013); A. R. Bazazi et al., "Preventing Opiate Overdose Deaths:
Examining Objections to Take-Home Naloxone," J Health Care Poor Underserved
21, no. 4 (2010); Maya Doe-Simkins et al., "Saved by the Nose: BystanderAdministered Intranasal Naloxone Hydrochloride for Opioid Overdose," American
Journal of Public Health 99, no. 5 (2009); S Burris, J Norland, and B Edlin, "Legal
Aspects of Providing Naloxone to Heroin Users in the United States," Int J Drug
Policy 12, no. 3 (2001).
52
Doe-Simkins et al., "Saved by the Nose: Bystander-Administered Intranasal
Naloxone Hydrochloride for Opioid Overdose; Burris, Norland, and Edlin, "Legal
Aspects of Providing Naloxone to Heroin Users in the United States."
53
See, e.g., Sporer and Kral, "Prescription Naloxone: A Novel Approach to Heroin
Overdose Prevention; Bridget M Kuehn, "Back from the Brink: Groups Urge Wide
Use of Opioid Antidote to Avert Overdoses," JAMA 311, no. 6 (2014); Beletsky et
al., "Physicians' Knowledge of and Willingness to Prescribe Naloxone to Reverse
Accidental Opiate Overdose: Challenges and Opportunities; Straus, Ghitza, and
Tai, "Preventing Deaths from Rising Opioid Overdose in the Us - the Promise of
Naloxone Antidote in Community-Based Naloxone Take-Home Programs."
54
Burris, Norland, and Edlin, "Legal Aspects of Providing Naloxone to Heroin
Users in the United States."
55
Doe-Simkins et al., "Saved by the Nose: Bystander-Administered Intranasal
Naloxone Hydrochloride for Opioid Overdose."
56
Beletsky, Rich, and Walley, "Prevention of Fatal Opioid Overdose; Burris,
Norland, and Edlin, "Legal Aspects of Providing Naloxone to Heroin Users in the
United States; Substance Abuse and Mental Health Services Administration,
"Opioid Overdose Prevention Toolkit."
57
New Mexico Administrative Code 7.32.7.8 Individual Authorization to
Administer Opioid Antagonist (2001) (Persons, other than a licensed health care
professional permitted by law to administer an opioid antagonist, are authorized to
administer an opioid antagonist to another person if he, in good faith, believes the
other person is experiencing an opioid drug overdose and he acts with reasonable
care in administering the drug to the other person. It is strongly recommended that
any person administering an opioid antagonist to another person immediately call
for Emergency Medical Services.)
58
State of New York Codes, Rules and Regulations 10.80.138 Opioid Overdose
Prevention Programs; New York State Public Health Law Article 33, Title 1, Sec.
3309.
59
Burris, Norland, and Edlin, "Legal Aspects of Providing Naloxone to Heroin
Users in the United States."
60
Ibid.
61
Ibid; Doe-Simkins et al., "Saved by the Nose: Bystander-Administered Intranasal
Naloxone Hydrochloride for Opioid Overdose."
62
Maxwell et al., "Prescribing Naloxone to Actively Injecting Heroin Users: A
Program to Reduce Heroin Overdose Deaths."
63
Burris, Norland, and Edlin, "Legal Aspects of Providing Naloxone to Heroin
Users in the United States."
Drug Policy Alliance | 131 West 33rd Street, 15th Floor, New York, NY 10001
nyc@drugpolicy.org | 212.613.8020 voice | 212.613.8021 fax
Page 8